Trial Profile
Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2020
Price :
$35
*
At a glance
- Drugs Plitidepsin (Primary) ; Bortezomib; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors PharmaMar
- 18 Jul 2018 Status changed from recruiting to discontinued.
- 07 Jul 2018 This trial has been completed in France.
- 04 Aug 2016 New trial record